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Abstract
Background: Prostate cancer is a common disease in men and at present there is no effective
therapy available due to its recurrence despite androgen deprivation therapy. The epidermal
growth factor receptor family (EGFR/HER1, HER2/neu and HER3)/PI3K/Akt signaling axis has been
implicated in prostate cancer development and progression. However, Erlotinib, an EGFR tyrosine
kinase inhibitor, has less effect on proliferation and apoptosis in prostate cancer cell lines. In this
study, we evaluate whether MP470, a novel receptor tyrosine kinase inhibitor alone or in
combination with Erlotinib has inhibitory effect on prostate cancer in vitro and in vivo.
Methods: The efficacy of MP470 or MP470 plus Erlotinib was evaluated in vitro using three prostate
cancer cell lines by MTS and apoptosis assays. The molecular mechanism study was carried out by
phosphorylation antibody array, immunoblotting and immunohistochemistry. A LNCaP mouse
xenograft model was also used to determine the tumor growth inhibition by MP470, Erlotinib or
the combination treatments.
Results: MP470 exhibits low μM IC50 in prostate cancer cell lines. Additive effects on both
cytotoxicity and induction of apoptosis were observed when LNCaP were treated with MP470 in
combination with Erlotinib. This combination treatment completely inhibited phosphorylation of
the HER family members (HER1, 2, 3), binding of PI3K regulatory unit p85 to HER3 and
downstream Akt activity even after androgen depletion. Furthermore, in a LNCaP mouse xenograft
model, the MP470-Erlotinib combination produced 30–65% dose-dependent tumor growth
inhibition (TGI).
Conclusion: We propose that MP470-Erlotinib targets the HER family/PI3K/Akt pathway and may
represent a novel therapeutic strategy for prostate cancer.
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Background
Prostate cancer is one of the leading causes of cancer mor-
tality in men, with an estimated 218,890 new patients and
27,050 deaths in the US in 2007 [1]. Utilization of pros-
tate-specific antigen (PSA) as a surrogate biomarker
results in earlier diagnosis of the disease [2]. Localized dis-
ease can be cured with radical prostatectomy or radiother-
apy [3]. However, patients with advanced or bulky local
disease are at increased risk of treatment failure following
local therapy [4]. Most patients remain largely asympto-
matic until the development of overt metastatic disease.
The current gold standard in men with newly diagnosed
metastatic disease is androgen deprivation therapy (ADT)
[5] which decreases the volume of the primary and meta-
static lesions by inducing apoptosis [6]. In most cases,
after an initial response, tumors recur as hormone-refrac-
tory prostate cancer (HRPC) and are unresponsive to
additional androgen withdrawal [7]. Clinical trials of tax-
ane-based therapy in HRPC have demonstrated a survival
benefit and increased time to progression [8]. However,
this therapy is not curative. Clinical trials are evaluating
novel regimens, including platinum agents (satraplatin),
microtubule stabilizing agents (epothilone B), mamma-
lian target of rapamycin (everolimus) and immunothera-
peutic vaccines [9]. Despite these advances, novel effective
therapies for prostate cancer based on mechanism of
action studies are urgently needed.
Receptor tyrosine kinases (RTKs) have emerged as new
drugable targets for treatment of several human solid and
hematological malignancies [10,11]. For example, imat-
inib mesylate (IM, Gleevec; Novartis), an inhibitor of Bcr-
Abl, c-Kit and platelet-derived growth factor receptor
(PDGFR), has been successfully used in the treatments of
chronic myeloid leukemia (CML) and gastrointestinal
stromal tumors (GISTs) [12]. Erlotinib (Tarceva; OSI
Pharmaceuticals), an inhibitor of the epidermal growth
factor receptor (EGFR), is also approved for the treatment
of patients with locally advanced or metastatic non-small
cell lung cancer and pancreatic carcinoma in combination
with gemcitabine [13]. RTKs are trans-membrane proteins
with a ligand-binding extracellular domain and a catalytic
intracellular kinase domain. The enzymatic activity of
RTKs is under tight control, so that non-proliferating cells
have very low levels of tyrosyl phosphorylated proteins.
Ligand binding leads to activation of the RTK and subse-
quent downstream signaling through the PI3K/Akt path-
way [14,15].
In human prostate cancer several RTKs including the
EGFR family (HER1, 2, and 3), PDGFR (alpha, beta), c-Ret
and ephrin (EPH) are over-expressed compared to normal
prostatic tissue [16-18], implicating pivotal roles in tum-
origenesis. Importantly, their downstream signaling leads
to constitutive activation of the PI3K/Akt pathway
[19,20], an important intracellular mediator involved in
proliferation, differentiation, inhibition of apoptosis,
tumorigenesis and angiogenesis [21,22]. It has been dem-
onstrated that Akt activity correlates with prostate cancer
progression and poor clinical outcome [23-26]. Support-
ing evidence for Akt inhibition as viable prostate cancer
therapy is provided by tumor growth inhibition in mice
with prostate cancer [27]. In addition, it has been shown
that activation of Akt also promotes androgen-independ-
ent progression of prostate cancer [28-31] and long-term
androgen ablation reinforces the PI3K/Akt pathway and
impedes its inhibition [32]. Therefore, suppression of the
RTK/PI3K/Akt pathway is hypothesized to serve as a novel
therapeutic intervention in advanced prostate cancer.
We utilized a structure-based approach to design a novel
RTK inhibitor, MP470, which effectively inhibits PDGFR,
c-Kit and c-Met. In contrast to Erlotinib or Imatinib,
MP470 inhibits cell proliferation, induces cell growth
arrest and promotes apoptosis in prostate LNCaP cancer
cells. Especially when combined with Erlotinib MP470
abolished HER family/PI3K/Akt pathway with associated
tumor growth inhibition in a LNCaP mouse xenograft
model.
Methods
Cells and reagents
LNCaP, PC-3 and DU145 prostate cancer cell lines used in
this study were purchased from American Type Culture
Collection (Rockville, MD) and maintained in RPMI 1640
medium (Mediatech, VA) supplemented with 10% fetal
bovine serum, 2 mM sodium pyruvate and 100 units/ml
penicillin/streptomycin at 37°C in a humidified atmos-
phere containing 5% CO2. NIH3T3, A549 and T47D cell
lines were obtained from Dr. Jesse Martinez lab (Arizona
Cancer Center, University of Arizona) and maintained in
the same medium as above. For the androgen-depletion
experiments, LNCaP cells were grown in androgen-
depleted medium, phenol red-free RPMI 1640 supple-
mented with 10% charcoal/dextran-treated FBS
(HyClone, Logan, UT). MP470 was kindly provided by
SuperGen (Dublin, CA) and Erlotinib [4-(3-ethynylphe-
nylamino)-6,7-bis(2-methoxyethoxy)quinazolium
hydrochloride] was isolated from clinical Tarceva tablets.
Imatinib mesylate (IM, Gleevec) was purchased from
Shanghai 21CEC Pharma. Ltd (Shanghai, China). The
compounds were dissolved at 5 mM in DMSO as a stock
solution, and then further diluted to desired concentra-
tions for in vitro experiments. Nocodazole was purchased
from Calbiochem (La Jolla, CA). Anti-PARP (H-250),
anti-ErbB-3 (C-17) and anti-EGFR (1005) antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-phospho-Akt (Ser473), anti-phospho-Akt
(Thr308), anti-Akt, anti-phospho-p44/42 Map Kinase
(Erk1/2) (Thr202/Tyr204) and anti-GAPDH (14C10)BMC Cancer 2009, 9:142 http://www.biomedcentral.com/1471-2407/9/142
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antibodies were from Cell Signaling Technology (Dan-
vers, MA). Anti-PI-3Kinase p85 antibody was purchased
from Upstate (Lake Pacific, NY). Anti-Phosphotyrosine
(PY20) was from BD Biosciences (San Jose, CA). Anti-
ErbB2 antibody was from Neomarkers (Fremont, CA).
Anti-β-actin antibody was from Sigma (St Louis, MO).
Analysis of cell proliferation inhibition (MTS assay)
The inhibition of cell proliferation was assessed by meas-
uring changes in total protein in a culture of each cell line
by use of a Sulforhodamine B (SRB) colorimetric assay.
Briefly, cells were seeded at 8,000 for LNCaP or 4000 for
PC-3 and DU145 per well onto flat-bottomed 96-well cul-
ture plates and allowed to grow for 24 hr followed by the
desired treatment. After 4 days incubation, cells were
quick rinsed with PBS and then fixed with 10% trichloro-
acetic acid (TCA) for 1 hr at 4°C. The cells were stained
with 50 μl of 0.04% Sulforhodamine B (S9012, Sigma) in
1% acetic acid for 20 min at room temperature, after
which the excess dye was removed by washing repeatedly
with 1% acetic acid. The protein-bound dye was dissolved
in 100 μl of 50 mM Tris-base solution for optical density
(OD) determination at 570 nm using a microplate reader.
Apoptosis assay
For routine analysis of apoptosis, treated cells were exam-
ined for apoptotic morphology using a fluorescence stain-
ing technique as described previously [33]. Briefly, cells
were exposed to DMSO or differing doses of MP470, Erlo-
tinib, or IM (1 to 10 μM) for 24 h and were harvested by
trypsinization. After staining with a mixed dye solution
containing 100 mg/ml each acridine orange and ethidium
bromide the morphology of the cells was observed by flu-
orescence microscopy, and the number of apoptotic cells
was quantified. In all cases a minimum of 200 cells were
counted for each sample. Using Annexin V staining to
detect apoptosis, treated cells were harvested by trypsini-
zation and rinsed with cold PBS once. After centrifugation
for 5 min, cells were resuspended in 500 μl of 1× Annexin
V binding buffer (BioVision, Annexin V-FITC Reagent Kit,
Cat.#1001-1000) and then added 1 μl of Annexin V-FITC
and 1 μl of Propidium Iodide (BioVision, Annexin V-FITC
Reagent Kit). After incubation for 5 min at room temper-
ature in the dark, the samples were analyzed by flow
cytometry.
Cell cycle analysis
LNCaP and PC-3 cells were treated with 10 μM of Erlo-
tinib, MP470, IM, Erlotinib plus MP470 or Erlotinib plus
IM for 32 hr and then left unsynchronized or synchro-
nized with 0.3 μg/ml Nocodazole (Sigma) for 16 hr. After
treatment with trypsin-EDTA, the cells were centrifuged at
1,500 × g for 5 min at 4°C and resuspended in PBS, fixed
by drop wise addition of ice-cold ethanol (100%) to a
final concentration of 70%, and incubated for 30 min on
ice. Fixed cells were pelleted and treated with 100 μl of
RNase A (0.2 mg/ml in PBS) for 5 min at room tempera-
ture, then suspended in 1 ml ddH2O and boiled for 10
min in a water bath. After staining with 4 μg/ml propid-
ium iodide, the DNA content was determined using a Bec-
ton Dickson flow cytometer and the cell cycle profile was
analyzed by ModFit software. Cell aggregates were gated
out of the analysis, based on the width of the propidium
iodide fluorescence signal. Each profile was compiled
from 10,000 gated events.
Cell stimulation by pervanadate
Cells were cultured to 70% confluence and starved for an
additional 24 hr with serum-free medium. After 4 hr pre-
treatment with MP470, Erlotinib, IM or combinations at
the appropriate concentrations, the cells were stimulated
by pervanadate (100 μM) for 10 min and then lysed for
protein analysis. Pervanadate stock solution (10 mM) was
freshly prepared by adding 50 μl of 200 mM sodium
orthovanadate (Na3VO4) and 250 μl of 200 mM hydrogen
peroxide (diluted from a 30% stock in 20 mM HEPES, pH
7.3) to 700 μl of 20 mM HEPES (pH 7.3).
Immunoblotting
The cells were lysed in NP-40 lysis buffer containing 50
mM Tris.Cl (pH 7.4), 0.15 M NaCl, 0.5% NP-40, 1 mM
DTT, 50 mM Sodium Fluoride, and 2 μl/ml Protease
inhibitor cocktail (Sigma, St. Louis, MO). Protein concen-
trations were determined using the BioRad protein assay
kit (Hercules, CA) and 50 μg of protein was resolved by
electrophoresis on a 10% SDS-PAGE gel. The proteins
were then transferred onto a nitrocellulose membrane
and nonspecific binding was blocked by incubating with
5% nonfat milk in TBST buffer (0.01 M Tris-Cl, 0.15 M
NaCl, 0.5% Tween-20, pH 8.0) at room temperature for 1
hr. The membrane was subjected to the indicated antibod-
ies and the proteins were detected by the SuperSignal West
Pico detection system (Pierce, Rockford, IL).
Immunoprecipitation
Cells were collected by scraping and lysed in Triton X-100
lysis buffer (50 mM HEPES, pH 7.5, 1.5 mM MgCl2, 150
mM NaCl, 20 mM NaF, 5 mM EDTA, 1% Triton X-100, 20
mM Na4P2O7, 1 mM NaVO4) supplemented with pro-
tease inhibitor cocktail on ice for 30 min. Lysates were
clarified by centrifugation at 13,000 × g for 8 min at 4°C.
Whole cell extracts were then incubated with 3 μg of PY20
anti-phosphotyrosine antibody overnight at 4°C for the
immunoprecipitation experiments or resolved by SDS-
PAGE and probed directly by Western blotting. Immune
complexes were collected on 30 μl of protein G agarose
bead (50%) slurry (Upstate) for 2 hr, washed in lysis
buffer four times, and eluted by boiling in SDS sampleBMC Cancer 2009, 9:142 http://www.biomedcentral.com/1471-2407/9/142
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buffer. Eluted proteins were then applied to SDS-PAGE
gels and probed by Western blotting with anti-PI-3K
(p85) antibody using the LI-Cor detection sysytem.
HER2 knock-down by small interfering RNA
Neu (HER2) siRNA (sc-29405) and control siRNA (sc-
37007) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Transfection reagent (DharmaFECT3)
was from Dharmacon, Inc. (Lafayette, CO). Cells were
grown to 70% confluence and transfected by siRNA at a
final concentration of 100 nM. 72 hr later the cells were
lysed for protein analysis.
Animal experiments
Animal care and treatment was performed at Arizona Can-
cer Center's experimental mouse shared services (EMSS)
core facility. Forty eight 6–7 week-old SCID male mice
were used. Each mouse was injected with 2× 107 LNCaP
cells subcutaneously into the right hind flank. One month
after inoculation, when tumors reached a volume of ~100
mm3, animals were divided randomly (pair-matched)
into four test groups each with 12 mice: control group
(DMSO), Erlotinib (80 mg/kg) group, MP470 (50 mg/kg)
group and Erlotinib plus MP470 group. TKIs was admin-
istered IP daily from days 1 to 24. The control group was
injected with 5% DMSO. A second study was also con-
ducted with MP470 at 10 mg/kg and 20 mg/kg with 80
mg/kg Erlotinib to assess for biological efficacy (pharma-
codynamics) and efficacy with 12 mice per group with the
control arm of 5% DMSO. The length (L) and width (W)
of the subcutaneous tumors were measured by calipers
and the tumor volume (TV) was calculated as: TV = (L ×
W2)/2. Mice were sacrificed at the end of treatment (2–3/
group), end of study or if they reached 2000 mm3 at any
time during the study. Excised tumors were either fixed in
paraffin or snap frozen for immunohistochemical analy-
sis.
Immunohistochemistry
The excised tumors were fixed in 10% neutral buffered
formalin (NBF) and embedded in paraffin. The 6 μM sec-
tions were deparaffinized in xylene and then rehydrated
in an ethanol series to distilled water. The sections were
blocked with blocking solution (0.2% BSA, 0.01%
saponin and 1% normal rabbit serum in PBS) for 1 hr at
room temperature. The slides were then immunostained
using anti-phospho Akt (Ser473) antibody at a dilution of
1:50 in blocking solution overnight at 4°C. After washing
3 times with PBS, the secondary antibody conjugated with
Cy3 (Sigma) was applied for 30 min at room temperature.
The signal was checked using florescence microscopy. Pri-
mary antibody replacement with normal serum from the
same animal species was used as the controls. Nuclei were
stained by propidium iodide.
Phosphorylation Antibody Array analyses
Human Phosphorylation Antibody Array (RayBiotech,
Norcross, GA) was employed to assay the relative levels of
phosphorylation of 71 different human RTKs after MP470
or Erlotinib or MP470 plus Erlotinib treatment. All the
solutions including cell lysis buffer, blocking buffer and
wash buffer were from this kit and the experiment was
performed following the manufacturer's instructions.
Briefly, the glass chips were blocked by 1× blocking buffer
for 1 hr at room temperature and 400 μg of cell lysates
were then added to the chips. After incubating at 4°C
overnight, arrays were washed and incubated with biotin-
conjugated anti-Phosphotyrosine for 2 hr, and then with
Alexa Fluor 555-conjugated streptavidin for 2 hr.
Unbound reagents were removed by washing, and the
bound antibodies on the chips were visualized using the
GenePix 4000B microarray scanner. The signal intensities
were analyzed and relative phosphorylation levels calcu-
lated with the GenePix Pro software (Molecular Devices,
Sunnyvale, CA).
Statistical Analysis
Analysis was done using multiple t-test (with Bonferroni
correction) with the STATA software package (StataCorp
LP, College Station, TX). Data was analyzed by group, p =
0.05 was considered significant.
Results
MP470 alone or in combination with Erlotinib inhibits 
prostate cancer cell proliferation, promotes cell cycle 
arrest and apoptosis
MP470, a novel receptor tyrosine kinase (RTK) inhibitor
has shown growth inhibitory activity against a variety of
cancer cell lines. MP470 is currently in Phase I clinical trial
testing. In this study, the cytotoxicity of MP470 was eval-
uated on prostate cancer cell lines (LNCaP, PC-3 and DU-
145). The drug was effective on LNCaP and PC-3 cells
with an IC50 of ~4 μM and 8 μM, respectively. However,
MP470 had only a modest effect on the viability of DU-
145 cells (Fig. 1A). Here we focused on LNCaP cells as it
is the most widely used in vitro model of prostate cancer
[34]. Since growing evidence implicates the HER family in
prostate cancer progression, we evaluated the cytotoxic
effect of Erlotinib [EGFR/HER1 tyrosine kinase inhibitor
(TKI)] on LNCaP cells and demonstrated a cytotoxic effect
with an IC50 of >10 μM. However, when Erlotinib (10 μM)
was combined with varying doses of MP470, the IC50 of
MP470 decreased to 2 μM (Fig. 1B). This indicates that
Erlotinib has an additive effect on the cytotoxicity of
MP470.
We next examined whether apoptosis is involved in the
inhibition of cell proliferation by MP470. LNCaP cells
were treated with DMSO and increasing doses of MP470BMC Cancer 2009, 9:142 http://www.biomedcentral.com/1471-2407/9/142
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(1, 2, 5, 10 μM) alone or in combination with Erlotinib
for 48 hr. Apoptosis quantified by morphologic changes
was induced in a dose-dependent manner and this effect
was synergistic with Erlotinib (Fig. 1C). Treatment of
LNCaP cells with either Erlotinib (10 μM) or MP470 (10
μM) induced 9% or 21% apoptosis respectively, while
apoptosis with the combination, increased to 36%. These
morphologic changes were confirmed by Annexin V stain-
ing and PARP cleavage assays (Fig. 1D and 1E) respec-
tively. Because MP470 inhibits c-Kit and PDGFR RTKs, we
evaluated Imatinib Mesylate (IM), a well-established c-Kit
and PDGFR TKI. IM had an IC50 of ~12 μM in LNCaP cells
[35] similar to that observed for Erlotinib alone. Interest-
ingly, IM did not induce apoptosis in LNCaP cells either
alone or in combination with Erlotinib (Fig. 1E). This
implies that c-Kit and PDGFR do not play a role in protect-
ing apoptosis and that MP470 inhibits LNCaP cells by a
mechanism independent of c-Kit and PDGFR.
In order to glean whether MP470 inhibits cell cycle pro-
gression, we treated the lung cancer cell line A549 and two
prostate cell lines, LNCaP and PC-3 with DMSO, 10 μM of
Erlotinib, MP470, IM or combinations for 32 hr. The cells
were then left unsynchronized or synchronized at the
Effects of MP470 or the MP470-Erlotinib combination on prostate cancer cell proliferation and apoptosis Figure 1
Effects of MP470 or the MP470-Erlotinib combination on prostate cancer cell proliferation and apoptosis. (a). 
LNCaP, DU145 and PC-3 cells were exposed to varying concentrations of MP470 for 4 days. Cell viability was assessed by MTS 
analysis. Points are the means of triplicate determinations ± SD. The IC50 for LNCaP and PC-3 is ~4 μM and 8 μM, respectively. 
Chemical structure of MP470 was shown at bottom. (b). LNCaP cells were exposed to varying concentrations of Erlotinib 
(Tarceva), MP470 or Erlotinib (10 μM) plus MP470 (varied concentrations) for 4 days. Cell viability was assessed by MTS anal-
ysis. IC50 was calculated with CalcuSyn software and the graph was shown. (c). LNCaP cells were treated with the indicated 
doses of Erlotinib or MP470 alone or in combination for 48 hr, and apoptosis was detected as morphologic change by fluores-
cent microscopy. Values are the means of three independent experiments ± SD. Control cells were treated with DMSO vehi-
cle. (d). LNCaP cells were treated with DMSO (control), 10 μM of Erlotinib or MP470 or in combination for 48 h. Flow 
cytometric analysis of apoptotic fraction based on propidium iodide (Y-axis) and annexin V staining (X-axis) showed up to 28% 
and 46% of apoptosis was induced by MP470 alone and in combination with Erlotinib, respectively. (e). LNCaP cells were 
treated with the indicated doses of Erlotinib or MP470 or IM alone or the combinations for 48 hr, and PARP cleavage was 
determined by immunoblotting with anti-PARP antibody. β-actin was used as a loading control. MP470 or MP470-Erlotinib but 
not Erlotinib or IM or Erlotinib-IM combination was shown to cause PARP cleavage in LNCaP cells.
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mitotic phase by nocodazole for 16 hr. Cell cycle progres-
sion analyzed by flow cytometry (Fig. 2) showed that
MP470 induced G1 arrest in A549 and LNCaP cells as they
cannot be synchronized in G2/M by nocodazole com-
pared to DMSO control. However, MP470 did not induce
G1 arrest in PC-3 cells, implicating that this arrest is cell
line specific. In addition, consistent with the above apop-
tosis data, we also observed a sub-G1 population in cells
treated with Erlotinib plus MP470 (Fig. 2). Together, our
data indicate that MP470 has inhibitory effects on cell
growth and cell cycle progression, promotes apoptosis
and that these effects are enhanced by Erlotinib.
A combination of MP470 and Erlotinib causes a further 
decrease in Akt activity compared with MP470 alone
Since MP470 or MP470 plus Erlotinib inhibited LNCaP
cell survival, we evaluated whether MP470 or MP470 plus
Erlotinib could inhibit Akt activation. As shown in figure
3A, Akt activity (as measured by phosphorylation on
Ser473) was significantly reduced by 10 μM MP470 alone
but was not reduced by Erlotinib or IM. Moreover, MP470
plus Erlotinib completely abolished Akt phosphorylation
in LNCaP cells with an unchanged total protein level of
Akt. It has been reported that PI3K and Akt activities are
increased following androgen deprivation [32], and acti-
vation of this pathway plays an essential role in the andro-
gen-refractory progression of prostate cancer by enhanced
cell proliferation and survival [30]. To further determine
whether MP470 or combination with Erlotinib continues
to inhibit Akt activity after androgen deprivation, LNCaP
cells were cultured in androgen-free medium for 10 days
and then treated with MP470, IM and Erlotinib alone or
in combination. Consistent with previous studies, the
phosphorylation of Akt at both Ser473 and Thr308 was
increased dramatically after androgen deprivation (Fig.
3B). MP470, especially in combination with Erlotinib
continues to inhibit these activating phosphorylation
events following androgen deprivation. However, Erlo-
tinib or IM alone or combination had no effect on Akt
phosphorylation.
MP470 plus Erlotinib Inhibits HER1, 2 and 3 
phosphorylation
Because MP470 or the combination of MP470 and Erlo-
tinib inhibits Akt phosphorylation, we next addressed
whether they affect the upstream components of the Akt
Cell cycle arrest induced by MP470 Figure 2
Cell cycle arrest induced by MP470. A549, LNCaP and PC-3 cells were treated with DMSO, 10 μM of Erlotinib, 
or MP470, or IM alone or the combinations for 32 hr and then treated with or without nocodazole for an addi-
tional 16 hr. Cells were harvested, fixed, treated with RNase, and then labeled with propidium iodide, and analyzed by flow 
cytometry (X-axis: DNA content, Y-axis: cell numbers). MP470 induced a G1 arrest in A549 and LNCaP but not in PC-3 cells.
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pathway. LNCaP and NIH3T3 cells were serum-starved for
24 hr, pre-treated with Erlotinib or MP470 or IM, Erlo-
tinib plus MP470 or Erlotinib plus IM at 2, 5 and 10 μM
for 4 hr, and then treated for 10 min with 100 μM per-
vanadate, a global protein tyrosine phosphatase inhibitor
that is commonly used to maintain tyrosine kinase phos-
phorylation in cells [36]. Initially, we detected the total
phosphotyrosine level by anti-phosphotyrosine antibody
(PY20) which showed a dramatic increase in phosphor-
ylation after pervanadate treatment (Fig. 4A and 4B).
MP470 alone or MP470 plus Erlotinib decreased total
tyrosine phosphorylation (Fig. 4A and 4B). Concomi-
tantly, Akt and Erk phosphorylation were also reduced by
MP470 or MP470 plus Erlotinib (Fig. 4A, B). Further,
MP470 plus Erlotinib blocked the interaction between the
PI3K p85 subunit and phosphorylated tyrosine kinases,
an essential process for PI3K activation (Fig. 4C). In con-
trast, Erlotinib and IM had no effect on tyrosine or Akt
phosphorylation, even when combined.
Since RTKs bind and activate PI3K and then Akt, we fur-
ther attempted to identify the RTKs which were targeted
by MP470 or MP470 plus Erlotinib. A phosphorylation
antibody array specifically designed to simultaneously
identify the relative levels of phosphorylation of 71 differ-
ent human RTKs was performed. Interestingly, the HER
family of receptors including the HER1 (EGFR), HER2
and HER3 was found to be affected (Fig. 5). To confirm
these, co-immunoprecipitation and immunoblotting
were performed and the results showed that phosphoryla-
tion of HER1, 2 and 3, binding of HER3 to PI3K p85, as
well as downstream Akt activity were dramatically sup-
pressed by MP470 plus Erlotinib in LNCaP (Fig. 6A) and
T47D breast cancer cells (Fig. 6B). To further study
whether HER family inhibition is involved in the regula-
tion of Akt phosphorylation, we utilized small interfer-
ence RNA (siRNA) to knockdown HER2 in LNCaP cells
which is highly expressed compared to HER1 and HER3,
and the data showed that Akt phosphorylation was
decreased after HER2 knockdown (Fig. 6C). Together,
these data imply that MP470 plus Erlotinib exquisitely
inhibits cell survival through the HER family/PI3K/Akt
pathway.
MP470 plus Erlotinib inhibits prostate cancer tumor 
growth in xenograft mice
We then evaluated the safety and efficacy of MP470, Erlo-
tinib and MP470 plus Erlotinib in a mouse LNCaP
xenograft model based on the cell culture mechanism of
action studies. Four LNCaP xenograft arms each with 12
MP470-Erlotinib combination markedly reduces protein  kinase activity Figure 4
MP470-Erlotinib combination markedly reduces pro-
tein kinase activity. (a-b). LNCaP (a) and NIH3T3 (b) cells 
were serum starved for 24 hr, pretreated with drugs as indi-
cated for 2 hr, and then treated with pervanadate (100 μM) 
for 10 min. Whole cell extracts were analyzed by immunob-
lotting for phosphorylated tyrosine kinases, phosphorylated 
Akt (Ser473), phosphorylated ERK1/2 (Thr202/Tyr204), and 
total Akt. (c). LNCaP cells were serum-starved for 24 hr, 
pretreated with DMSO, 10 μM of MP470 or MP470-Erlo-
tinib, and then stimulated by pervanadate for 10 min. For 
immunoprecipitation (IP) assays, whole cell extracts (WCE) 
containing equal amounts of protein were incubated with 
anti-phosphotyrosine (PY20) antibodies overnight at 4°C. 
Immune complexes were enriched by Protein G-Agarose 
beads and probed by Western blotting for the p85 subunit of 
PI3K.
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C
Effects of MP470, Erlotinib, and MP470-Erlotinib treatment  on Akt activity Figure 3
Effects of MP470, Erlotinib, and MP470-Erlotinib 
treatment on Akt activity. (a). LNCaP cells were treated 
with DMSO or different doses of Erlotinib, MP470, IM or 
combinations as indicated for 30 hr. Phospho(Ser473)-Akt 
and total Akt were detected by immunoblotting. β-actin anti-
body was used as the loading control. (b). LNCaP cells were 
grown in androgen-depleted medium, phenol red-free RPMI 
1640 supplemented with 10% charcoal/dextran-treated FBS 
for 10 days. The cells were treated with 10 μM of Erlotinib, 
MP470, IM alone or Erlotinib plus MP470 and Erlotinib plus 
IM for 24 hr, and Akt phosphorylation was analyzed by 
Western blotting.
β-actin
Phospho-Akt
(Ser473)
25 1 0 DMSO Erlotinib
25 1 0
MP470
25 1 0
Imatinib
25 1 0
Erl.+MP.
25 1 0
Erl.+Ima.
μM
Total Akt
A
β-actin
P-Akt308
P-Akt473
DMSO
Erlotinib
MP470
Imatinib
Erl.+MP470
Erl.+Imatinib BBMC Cancer 2009, 9:142 http://www.biomedcentral.com/1471-2407/9/142
Page 8 of 12
(page number not for citation purposes)
mice were dosed intraperitoneally with DMSO (control)
or Erlotinib 80 mg/kg or MP470 50 mg/kg or Erlotinib 80
mg/kg plus MP470 50 mg/kg daily for 2 weeks and then
observed for a further 11 days (Fig. 7A). Individual ther-
apy with MP470 or Erlotinib showed modest tumor
growth inhibition (TGI), while MP470 plus Erlotinib had
a marked effect on TGI (45–65%). However, due to the
high doses of MP470 used, only five or one mouse
remained alive in the combination arm at the end of treat-
ment or at the end of the study, respectively. We therefore
reduced the MP470 dose to 10 mg/kg or 20 mg/kg for the
combination treatment. As shown in figure 7B, TGI in the
group receiving 10 mg/kg MP470 + 80 mg/kg Erlotinib
was not significantly different from the control group.
However, mice receiving 20 mg/kg MP470 + 80 mg/kg
Erlotinib had a significant TGI compared to the control
group (p = 0.01). To determine whether the biological
effect(s) of MP470 plus Erlotinib are correlated to its abil-
ity to inhibit Akt activation, Akt phosphorylation in
tumor tissue at the end of treatment from the different
treatment groups was analyzed by immunohistochemis-
try. Figure 8 showed Akt phosphorylation was abolished
in the combination arm (MP470 plus Erlotinib) com-
pared to control or individual therapies. Together, these
observations indicate that the combination of MP470 and
Erlotinib inhibits Akt with an associated TGI.
Discussion
Single agent therapy with small molecule TKIs is effective
in malignancies dependent on mutated constitutively
activated RTKs [e.g. Kit/a-PDGFR in GIST (IM, Sunitinib),
EGFR in NSCLC and GBM (Erlotinib)] and non-RTKs
such as, Bcr-Abl in CML (IM, Dasatinib). However,
chronic therapy with a single TKI eventually becomes inef-
fective due to acquired mechanisms of resistance. In con-
trast, single agent TKIs is less effective in tumors that
amplify and over-express RTKs such as the EGFR family
(HER1 in head and neck cancer, HER2 in breast cancer,
HER1 and 2 in pancreas cancer). Clinical efficacy studies
reported that the HER1 selective Erlotinib and Gefitinib,
the HER1/HER2 selective Lapatanib and the pan-HER
selective Canertinib have shown limited activity in the
treatment of HER2 over-expressing breast cancer, despite
evidence suggesting these cancers are highly dependent on
HER2 function [37]. Correlative data from tumor biopsies
confirm that TKIs reach their molecular targets and sup-
press the activity of EGFR, HER2 and MAPK signaling.
However, inactivation of Akt signaling is not apparent
suggesting that HER2 signaling is not completely sup-
pressed by these therapies. Therefore, critical studies are
required to determine mechanisms by which the HER
Effects of MP470-Erlotinib combination on tyrosine phospho- rylation of the HER family and PI3K/Akt Figure 6
Effects of MP470-Erlotinib combination on tyrosine 
phosphorylation of the HER family and PI3K/Akt. 
LNCaP (a) and T47D (b) cells were serum starved for 24 hr, 
pretreated with 10 μM drug as indicated for 2 hr, and then 
treated with pervanadate (100 μM) for 10 min. Cell extracts 
were incubated with anti-EGFR, anti-HER2 and anti-HER3 
antibodies at 4°C overnight. The immune complexes were 
enriched by Protein G-Agarose beads and probed by immu-
noblotting for phosphotyrosine (PY20) and the p85 regularly 
subunit of PI3K. Western blotting analysis for phosphor-
ylated Akt was performed in T47D cells. (c). SiRNA knock-
down of HER2 decreased phosphorylated Akt. LNCaP cells 
were grown to 70% confluence and treated with non-target-
ing siRNA (control RNAi) and siRNA against HER2 at a con-
centration of 100 nmol/L. At 72 hr, cells were harvested to 
detect HER2, phosphorylated Akt and total Akt by Western 
blotting. GAPDH was used as a loading control.
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Effects of MP470-Erlotinib combination on phosphorylation  of different human RTKs Figure 5
Effects of MP470-Erlotinib combination on phosphor-
ylation of different human RTKs. LNCaP cells were 
serum starved for 24 hr, pretreated with DMSO (control), 
Erlotinib (10 μM), MP470 (10 μM), or MP470-Erlotinib (10 
μM each) for 2 hr, and then treated with pervanadate (100 
μM) for 10 min. For Phosphorylation Antibody Array analy-
sis, 400 μg of cell lysates were incubated with the glass chips 
at 4°C overnight. After washing for several times, the arrays 
were incubated with biotin-conjugated anti-Phosphotyrosine 
for 2 hr, and then with Alexa Fluor 555-conjugated streptavi-
din for 2 hr. Unbound reagents were removed by washing, 
and the bound antibodies on the chips were visualized using 
the GenePix 4000B microarray scanner.
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family over expressing tumors evade targeted therapy and
to identify novel combination TKI therapies to suppress
the PI3K/AKT survival pathway. In this study, cell-based
evaluation showed that MP470, a novel tyrosine kinase
inhibitor inhibited cell proliferation, induced growth
arrest and promoted apoptosis in prostate cancer cells. In
addition, the combination treatment of MP470 and Erlo-
tinib completely inhibited HER family activation, and the
downstream signaling pathway PI3K/Akt in LNCaP and
T47D cells. Moreover, MP470 plus Erlotinib significantly
suppressed tumor growth in an LNCaP mouse xenograft
model, suggesting it could be used as a new combination
for prostate cancer treatment.
In prostate cancer, Akt has been shown to be constitu-
tively activated due to loss of PTEN, which negatively reg-
ulates PI3K. Clinical reports indicate that Akt is
significantly over-expressed in prostate tumors compared
to benign prostatic tissue, and its level is directly corre-
lated with tumor progression and prostate-specific anti-
gen (PSA) serum levels, as well as a higher Gleason score
[23,26]. In addition, increased phosphorylation of Akt
(Ser473) has been shown to be an excellent predictor of
poor clinical outcome in prostate cancer [25]. Moreover,
stable over-expression of constitutively active Akt dramat-
ically enhances LNCaP xenograft tumor growth in intact
male nude mice [24]. In contrast, inhibition of PI3K or
Akt induces apoptosis in LNCaP cells and tumor growth
suppression in vivo [38,39]. Consequently, Akt inhibition
is a rational therapy or an endpoint of therapy in prostate
cancer. Indeed, clinical studies with agents known to act
through Akt inhibition show promise [40]. Consistent
with these, in this study we showed that an MP470-Erlo-
tinib combination completely inhibits Akt activity which
The MP470-Erlotinib combination causes TGI in an LNCaP xenograft mouse model Figure 7
The MP470-Erlotinib combination causes TGI in an LNCaP xenograft mouse model. (a). 2 × 107 LNCaP cells were 
injected into the flanks of SCID male mice and tumors grown for 4 weeks to achieve a volume of ~100 mm3. The mice were 
pair matched into different groups (12 mice/group). The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/
kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor vol-
ume ± SEM are graphed. * P-value = 0.008. (b). 2 × 107 LNCaP cells were injected into the flanks of SCID male mice and three 
groups (12 mice/group) were pair matched when the tumors grew to ~300 mm3. The mice were treated with DMSO (con-
trol), Erlotinib (80 mg/kg) plus MP470 (10 mg/kg or 20 mg/kg, respectively) by IP daily for 22 days (starting day 27 and ending 
day 49), and the mean tumor volume ± SEM are graphed. * P-value = 0.01.
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may contribute to the tumor suppression seen in an
LNCaP xenograft mouse model. In addition, hormone-
refractory prostate cancer is a major clinical obstacle as
there are no drugs to halt its progression [3]. Previous
studies have shown that PI3K/Akt activation is associated
with prostate cancer progression from an androgen-
dependent to an androgen-independent state [30]. In
androgen-ablated LNCaP cells, PI3K/Akt activity is ele-
vated and required for growth and survival [31] and inhi-
bition can restore sensitivity to apoptosis induction [32].
In a mouse xenograft model of LNCaP, conditional Akt
activation promotes tumor growth in castrated animals by
enhanced cell proliferation and inhibition of apoptosis
[28]. Thus, blockage of Akt activity should prove benefi-
cial for hormone-refractory prostate cancer. Our experi-
ments showed that the MP470-Erlotinib combination
efficiently inhibited Akt activity in androgen-ablated
LNCaP cells (Fig. 3B), suggesting that this combination
may be a viable treatment modality in patients failing
androgen blockade or can be administered with andro-
gens in front-line therapy to prevent hormone refractory
status.
Except for the loss of PTEN function, PI3K/Akt signaling is
often dysregulated in human cancer due to constitutive
activation of receptor tyrosine kinases (RTKs) [41]. Of the
known RTKs, activation of the HER family (HER1, 2 and
3) and the PDGFR family has been demonstrated to asso-
ciate with prostate cancer progression [16,19]. In prostate
cancer cell lines, HER family receptors are over-expressed
[42,43] and inhibition with specific TKIs has shown anti-
tumor effects in vitro and  in vivo [44,45]. HER family
members are also widely expressed in cancerous tissues of
the prostate and significant over-expression is found in
hormone-refractory prostate cancer and metastatic tissue
compared to localized prostate cancer [46]. Hence, HER
family receptors have become potential therapeutic tar-
gets in prostate cancer [47]. MP470, designed as an ATP-
competitive TKI was very effective in inhibiting tyrosine
phosphorylation in LNCaP and NIH3T3 cells after per-
vanadate stimulation (Fig. 4A and 4B). Further, the
MP470-Erlotinib combination completely inhibited tyro-
sine phosphorylation and p85 binding (Fig. 4C) as well as
Akt activity. The RTK phospho-antibody assay identified
the HER family (HER1, HER2 and HER3) in LNCaP cells
as targeted by MP470 (Fig. 5A). Erlotinib or MP470 alone
did not totally inhibit phosphorylation of the HER family.
However, MP470-Erlotinib combination completely
inhibited the phosphorylation of HER1, HER2 and HER3,
the binding of PI3K regulatory subunit p85 to HER3 and
downstream Akt activity (Fig. 5B and 5C). Due to the
cross-talk between the individual members of the HER
family or between the HER family and other RTKs, evi-
dence indicates that targeting a single RTK is inadequate as
a therapeutic modality in cancer therapy [48,49]. In gefit-
inib-resistant NSCLC cell lines, c-Met, an oncogenic RTK
phosphorylates HER3 and leads to activation of the PI3K/
Akt pathway. Treatment of the resistant cells with a TKI
specific for c-Met or gefitinib alone did not inhibit cell via-
bility or affect HER3 and Akt phosphorylation. However,
the combination of both drugs inhibited resistant cell
growth and prevented HER3 and Akt phosphorylation
[50]. Because MP470 does inhibit c-Met activation (data
not shown), as well as c-Kit and Axl[51], it is likely that
one or more of these RTKs cross-talk with the HER family
members and activate them. Therefore, inhibition of
HER1 and HER2 by Erlotinib and multi-targeted RTK
inhibition by MP470 may explain the complete inhibi-
tion of the HER3/PI3K/Akt pathway by Erlotinib-MP470
combination in LNCaP cells. However, further studies are
required to identify potential target(s) of MP470 in
LNCaP cells for confirming this hypothesis.
Conclusion
MP470, a novel receptor tyrosine kinase inhibitor effec-
tively inhibits cell proliferation in prostate cancer cell
lines. When combined with Erlotinib, MP470 induced
apoptosis and cell growth arrest with abolition of tumor
growth in a dose-dependent manner in an LNCaP
xenograft mouse model. The HER family and the phos-
phorylation of downstream Akt are inhibited by this
novel TKI combination. Hence, blockade of HER family/
PI3K/Akt may represent a useful treatment modality for
prostate cancer. The safety and efficacy of the MP470-Erlo-
tinib combination is currently being evaluated in a Phase
I clinical trial for refractory solid tumors and results are
awaited with enthusiasm.
Effects of MP470-Erlotinib combination on Akt phosphoryla- tion in xenograft tissues Figure 8
Effects of MP470-Erlotinib combination on Akt phos-
phorylation in xenograft tissues. IHC analysis for Akt 
activity was performed on the tumors harvested at the end 
of the treatment of an LNCaP xenograft mouse model. Paraf-
fin embedded sections were immuno-stained for expression 
of phosphorylated Akt (Ser473). Tumors from mice treated 
with the MP470-Erlotinib combination had a near complete 
inhibition of Akt phosphorylation compared to control or 
individual therapies (200 ×).
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